Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS

Journal of Leukocyte Biology

Volumn 87, Issue 6, 2010, Pages 1103-1114

  Halili, Maria A ^a   Andrews, Melanie R ^a   Labzin, Larisa I ^a   Schroder, Kate ^b   Matthias, Gabriele ^c   Cao, Chun ^c   Lovelace, Erica ^a   Reid, Robert C ^a   Le, Giang T ^a   Hume, David A ^d   Irvine, Katharine M ^a   Matthias, Patrick ^c   Fairlie, David P ^a   Sweet, Matthew J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

HDAC6; Histone deacetylase; Inflammation; SAHA; Sepsis; TLR

Indexed keywords

CYCLOOXYGENASE 2; ENDOTHELIN 1; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 12P40; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 3; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; THIOISOBUTYRIC ACID(6 TERT BUTOXYCARBONYLAMINO 6 CYCLOPENTYLCARBAMOYLHEXYL)ESTER; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; AUTACOID; HDAC6 PROTEIN, MOUSE; HISTONE DEACETYLASE; HYDROXAMIC ACID; LUCIFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PTGS2 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 4;

ACETYLATION; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG EFFECT; GENE EXPRESSION; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN SECRETION; ANIMAL; C57BL MOUSE; CHEMISTRY; CHROMATIN IMMUNOPRECIPITATION; CYTOLOGY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; CYCLOOXYGENASE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-12 SUBUNIT P40; LIPOPOLYSACCHARIDES; LUCIFERASES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLASMINOGEN ACTIVATOR INHIBITOR 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TOLL-LIKE RECEPTOR 4;

EID: 77954013043     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0509363     Document Type: Article

References (50)

1. Minucci, S., Pelicci, P. G. (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51.
2. De Ruijter, A. J. M., van Gennip, A. H., Caron, H. N., Kemp, S., Kuilenburg, A. B. P. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370, 737-749. (Pubitemid 36399066)
3. Porcu, M., Chiarugi, A. (2005) The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol. Sci. 26, 94-103. (Pubitemid 40170172)
4. Marks, P. A., Breslow, R. (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25, 84-90.
5. Blanchard, F., Chipoy, C. (2005) Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov. Today 10, 197-204.
6. Duvic, M., Vu, J. (2007) Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Investig. Drugs 16, 1111-1120.
7. Hu, E., Dul, E., Sung, C-M., Chen, Z., Kirkpatrick, R., Zhang, G-F., Johanson, K., Liu, R., Lago, A., Hofmann, G., Macarron, R., de los Frailes, M., Perez, P., Krawiec, J., Winkler, J., Jaye, M. (2003) Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307, 720-728.
8. Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., Schreiber, S. L. (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 100, 4389-4394.
9. Suzuki, T., Kouketsu, A., Itoh, Y., Hisakawa, S., Maeda, S., Yoshida, M., Nakagawa, H., Miyata, N. (2006) Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J. Med. Chem. 49, 4809-4812. (Pubitemid 44201038)
10. Kozikowski, A. P., Tapadar, S., Luchini, D. N., Kim, K. H., Billadeau, D. D. (2008) Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J. Med. Chem. 51, 4370-4373.
11. Dinarello, C. A. (2006) Inhibitors of histone deacetylases as anti-inflammatory drugs. Ernst Schering Res. Found. Workshop, 45-60.
12. Halili, M. A., Andrews, M. R., Sweet, M. J., Fairlie, D. P. (2009) Histone deacetylase inhibitors in inflammatory disease. Curr. Top. Med. Chem. 9, 309-319.
13. Leoni, F., Zaliani, A., Bertolini, G., Porro, G., Pagani, P., Pozzi, P., Donà, G., Fossata, G., Sozzani, S., Azam, T., Bufler, P., Fantuzzi, G., Goncharov, I., Kim, S-H., Pomerantz, B. J., Reznikov, L. L., Siegmund, B., Dinarello, C. A., Mascagni, P. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. USA 99, 2995-3000.
14. Lin, H-S., Hu, C-Y., Chan, H-Y., Liew, Y-Y., Huang, H-P., Lepescheux, L., Bastianelli, E., Baron, R., Rawadi, G., Clement-Lacroix, P. (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150, 862-872. (Pubitemid 46536628)
15. Camelo, S., Iglesias, A. H., Hwang, D., Due, B., Ryu, H., Smith, K., Gray, S. G., Imitola, J., Duran, G., Assaf, B., Langley, B., Khoury, S. J., Stephanopoulos, G., De Girolami, U., Ratan, R. R., Ferrante, R. J., Dangond, F. (2005) Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 164, 10-21.
16. Chung, Y. L., Lee, M. Y., Wang, A. J., Yao, L. F. (2003) A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 8, 707-717.
17. Choi, J. H., Oh, S. W., Kang, M. S., Kwon, H. J., Oh, G. T., Kim, D. Y. (2005) Trichostatin A attenuates airway inflammation in mouse asthma model. Clin. Exp. Allergy 35, 89-96. (Pubitemid 40188276)
18. Segain, J. P., Raingeard de la Bletiere, D., Leray, V., Gervois, N., Rosales, C., Ferrier, L., Bonnet, C., Blottiere, H. M., Galmiche, J. P. (2000) Butyrate inhibits inflammatory responses through NF-κB inhibition: implications for Crohn's disease. Gut 47, 397-403.
19. Kim, H. J., Rowe, M., Ren, M., Hong, J-S., Chen, P-S., Chuang, D-M. (2007) Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321, 892-901. (Pubitemid 46762687)
20. Choi, J-H., Nam, K-H., Kim, J., Baek, M. W., Park, J-E., Park, H-Y., Kwon, H. J., Kwon, O-S., Kim, D-Y., Oh, G. T. (2005) Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25, 2404-2409. (Pubitemid 41552662)
21. Barnes, P. J., Adcock, I. M., Ito, K. (2005) Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 25, 552-563. (Pubitemid 40331188)
22. Ito, K., Yamamura, S., Essilfie-Quaye, S., Cosio, B., Ito, M., Barnes, P. J., Adcock, I. M. (2006) Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression. J. Exp. Med. 203, 7-13. (Pubitemid 43139638)
23. Aung, H. T., Schroder, K., Himes, S. R., Brion, K., van Zuylen, W., Trieu, A., Suzuki, H., Hayashizaki, Y., Hume, D. A., Sweet, M. J., Ravasi, T. (2006) LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J. 20, 1315-1327. (Pubitemid 44943839)
24. Bode, K. A., Schroder, K., Hume, D. A., Ravasi, T., Heeg, K., Sweet, M. J., Dalpke, A. H. (2007) Histone deacetylase inhibitors decrease Toll-like receptor mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 122, 596-606. (Pubitemid 350075958)
25. Brogdon, J. L., Xu, Y., Szabo, S. J., Buxton, F., Huang, Q. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109, 1123-1130. (Pubitemid 46220659)
26. Cao, W., Bao, C., Padalko, E., Lowenstein, C. J. (2008) Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J. Exp. Med. 205, 1491-1503. (Pubitemid 351831502)
27. Nusinzon, I., Horvath, C. M. (2006) Positive and negative regulation of the innate antiviral response and β-interferon gene expression by deacetylation. Mol. Cell. Biol. 26, 3106-3113.
28. Deng, W. G., Zhu, Y., Wu, K. K. (2004) Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 103, 2135-2142. (Pubitemid 38326230)
29. Schroder, K., Spille, M., Pilz, A., Lattin, J., Bode, K. A., Irvine, K. M., Burrows, A. D., Ravasi, T., Weighardt, H., Stacey, K. J., Decker, T., Hume, D. A., Dalpke, A. H., Sweet, M. J. (2007) Differential effects of CpG DNA on IFN-β induction and STAT1 activation in murine macrophages versus dendritic cells: alternatively activated STAT1 negatively regulates TLR signaling in macrophages. J. Immunol. 179, 3495-3503.
30. Schroder, K., Lichtinger, M., Irvine, K. M., Brion, K., Trieu, A., Ross, I. L., Ravasi, T., Stacey, K. J., Rehli, M., Hume, D. A., Sweet, M. J. (2007) PU.1 and ICSBP control constitutive and IFN-γ-regulated Tlr9 gene expression in mouse macrophages. J. Leukoc. Biol. 81, 1577-1590. (Pubitemid 46827980)
31. Tallack, M. R., Keys, J. R., Perkins, A. C. (2007) Erythroid Kruppel-like factor regulates the G1 cyclin dependent kinase inhibitor p18INK4c. J. Mol. Biol. 369, 313-321.
32. Gómez-Hernández, A., Martín-Ventura, J. L., Sánchez-Gálan, E., Vidal, C., Ortego, M., Blanco-Colio, L. M., Ortega, L., Tuñon, J., Egido, J. (2006) Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-κB. Atherosclerosis 187, 139-149. (Pubitemid 43817006)
33. 2-dependent plaque instability. Circulation 104, 921-927.
34. Westrick, R. J., Eitzman, D. T. (2007) Plasminogen activator inhibitor-1 in vascular thrombosis. Curr. Drug Targets 8, 966-1002.
35. Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., Seiser, C. (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21, 2672-2681. (Pubitemid 34619383)
36. Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M., Carducci, M. A., Atadja, P., Pili, R. (2006) Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 α. Cancer Res. 66, 8814-8821. (Pubitemid 44449199)
37. Peyssonnaux, C., Cejudo-Martin, P., Doedens, A., Zinkernagel, A. S., Johnson, R. S., Nizet, V. (2007) Cutting edge: essential role of hypoxia inducible factor-1α in development of lipopolysaccharide-induced sepsis. J. Immunol. 178, 7516-7519.
38. Blouin, C. C., Page, E. L., Soucy, G. M., Richard, D. E. (2004) Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1α. Blood 103, 1124-1130.
39. Zhang, Y., Kwon, S., Yamaguchi, T., Cubizolles, F., Rousseaux, S., Kneissel, M., Cao, C., Cheng, H-L., Chua, K., Lombard, D., Mizeracki, A., Matthias, G., Alt, F. W., Khochbin, S., Matthias, P. (2008) Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell. Biol. 28, 1688-1701.
40. Lane, A. A., Chabner, B. A. (2009) Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27, 5459-5468.
41. Suuronen, T., Huuskonen, J., Pihlaja, R., Kyrylenko, S., Salminen, A. (2003) Regulation of microglial inflammatory response by histone deacetylase inhibitors. J. Neurochem. 87, 407-416.
42. Lu, S. C., Wu, H. W., Lin, Y. J., Chang, S. F. (2009) The essential role of Oct-2 in LPS-induced expression of iNOS in RAW 264.7 macrophages and its regulation by trichostatin A. Am. J. Physiol. Cell Physiol. 296, C1133-C1139.
43. Hirose, N., Maekawa, T., Shinagawa, T., Ishii, S. (2009) ATF-2 regulates lipopolysaccharide-induced transcription in macrophage cells. Biochem. Biophys. Res. Commun. 385, 72-77.
44. Wang, J., Mahmud, S. A., Bitterman, P. B., Huo, Y., Slungaard, A. (2007) Histone deacetylase inhibitors suppress TF-κB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. J. Biol. Chem. 282, 28408-28418. (Pubitemid 47606006)
45. Grabiec, A. M., Krausz, S., de Jager, W., Burakowski, T., Groot, D., Sanders, M. E., Prakken, B. J., Maslinski, W., Eldering, E., Tak, P. P., Reedquist, K. A. (2010) Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J. Immunol. 184, 2718-2728.
46. Hämäläinen, M., Lilja, R., Kankaanranta, H., Moilanen, E. (2008) Inhibition of iNOS expression and NO production by anti-inflammatory steroids: reversal by histone deacetylase inhibitors. Pulm. Pharmacol. Ther. 21, 331-339. (Pubitemid 351312675)
47. Jungel, A., Baresova, V., Ospelt, C., Simmen, B. R., Michel, B. A., Gay, R. E., Gay, S., Seemayer, C. A., Neidhart, M. (2006) Trichostatin A sensitizes rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis. Ann. Rheum. Dis. 65, 910-912.
48. Villagra, A., Cheng, F., Wang, H. W., Suarez, I., Glozak, M., Maurin, M., Nguyen, D., Wright, K. L., Atadja, P. W., Bhalla, K., Pinilla-Ibarz, J., Seto, E., Sotomayor, E. M. (2009) The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol. 10, 92-100.
49. Laribee, R. N., Klemsz, M. J. (2001) Loss of PU.1 expression following inhibition of histone dacetylases. J. Immunol. 167, 5160-5166. (Pubitemid 33009752)
50. Laribee, R. N., Klemsz, M. J. (2005) Histone H4 HDAC activity is necessary for expression of the PU.1 gene. Biochim. Biophys. Acta 1730, 226-234.